Clinuvel Pharmaceuticals Statistics

Total Valuation

FRA:UR9 has a market cap or net worth of EUR 352.86 million. The enterprise value is 225.40 million.

Market Cap	352.86M
Enterprise Value	225.40M

Important Dates

The last earnings date was Thursday, November 27, 2025.

Earnings Date	Nov 27, 2025
Ex-Dividend Date	Sep 4, 2025

Share Statistics

Current Share Class	50.20M
Shares Outstanding	n/a
Shares Change (YoY)	-1.27%
Shares Change (QoQ)	+0.44%
Owned by Insiders (%)	10.26%
Owned by Institutions (%)	20.97%
Float	41.56M

Valuation Ratios

The trailing PE ratio is 17.47 and the forward PE ratio is 16.64.

PE Ratio	17.47
Forward PE	16.64
PS Ratio	6.65
PB Ratio	2.62
P/TBV Ratio	2.63
P/FCF Ratio	15.49
P/OCF Ratio	15.38
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.43, with an EV/FCF ratio of 9.90.

EV / Earnings	11.16
EV / Sales	4.16
EV / EBITDA	8.43
EV / EBIT	8.64
EV / FCF	9.90

Financial Position

The company has a current ratio of 9.66, with a Debt / Equity ratio of 0.00.

Current Ratio	9.66
Quick Ratio	9.25
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.01
Interest Coverage	10.25

Financial Efficiency

Return on equity (ROE) is 16.30% and return on invested capital (ROIC) is 12.85%.

Return on Equity (ROE)	16.30%
Return on Assets (ROA)	11.37%
Return on Invested Capital (ROIC)	12.85%
Return on Capital Employed (ROCE)	18.71%
Revenue Per Employee	3.32M
Profits Per Employee	1.26M
Employee Count	16
Asset Turnover	0.38
Inventory Turnover	0.87

Taxes

In the past 12 months, FRA:UR9 has paid 8.59 million in taxes.

Income Tax	8.59M
Effective Tax Rate	29.83%

Stock Price Statistics

The stock price has decreased by -14.84% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-14.84%
50-Day Moving Average	6.41
200-Day Moving Average	6.34
Relative Strength Index (RSI)	61.82
Average Volume (20 Days)	227

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:UR9 had revenue of EUR 53.04 million and earned 20.19 million in profits. Earnings per share was 0.40.

Revenue	53.04M
Gross Profit	48.31M
Operating Income	25.54M
Pretax Income	28.78M
Net Income	20.19M
EBITDA	25.98M
EBIT	25.54M
Earnings Per Share (EPS)	0.40

Full Income Statement

Balance Sheet

The company has 125.11 million in cash and 295,051 in debt, giving a net cash position of 124.81 million.

Cash & Cash Equivalents	125.11M
Total Debt	295,051
Net Cash	124.81M
Net Cash Per Share	n/a
Equity (Book Value)	134.43M
Book Value Per Share	2.68
Working Capital	131.61M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 22.94 million and capital expenditures -166,675, giving a free cash flow of 22.77 million.

Operating Cash Flow	22.94M
Capital Expenditures	-166,675
Free Cash Flow	22.77M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 91.08%, with operating and profit margins of 48.16% and 38.07%.

Gross Margin	91.08%
Operating Margin	48.16%
Pretax Margin	54.26%
Profit Margin	38.07%
EBITDA Margin	48.98%
EBIT Margin	48.16%
FCF Margin	42.94%

Dividends & Yields

This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 0.42%.

Dividend Per Share	0.03
Dividend Yield	0.42%
Dividend Growth (YoY)	-7.58%
Years of Dividend Growth	7
Payout Ratio	6.92%
Buyback Yield	1.27%
Shareholder Yield	1.69%
Earnings Yield	5.72%
FCF Yield	6.45%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on November 12, 2010. It was a reverse split with a ratio of 0.1.

Last Split Date	Nov 12, 2010
Split Type	Reverse
Split Ratio	0.1

Scores

FRA:UR9 has an Altman Z-Score of 14.53 and a Piotroski F-Score of 5.

Altman Z-Score	14.53
Piotroski F-Score	5